Recently, we found that a major oncogene in cancer, MYC, becomes deregulated in MRT through loss of SNF5 [7], a finding that explains the activation of MYC target gene signatures observed in SMARCB1-deficient cancers [12–14]. This evidence concerns the gene SMARCB1 and cancer.